EP3403093A4 - PLASMATIC AUTO-ANTIBODY BIOMARKERS FOR THE DIAGNOSIS OF LUNG CANCER - Google Patents

PLASMATIC AUTO-ANTIBODY BIOMARKERS FOR THE DIAGNOSIS OF LUNG CANCER Download PDF

Info

Publication number
EP3403093A4
EP3403093A4 EP17738868.3A EP17738868A EP3403093A4 EP 3403093 A4 EP3403093 A4 EP 3403093A4 EP 17738868 A EP17738868 A EP 17738868A EP 3403093 A4 EP3403093 A4 EP 3403093A4
Authority
EP
European Patent Office
Prior art keywords
plasmatic
auto
diagnosis
lung cancer
antibody biomarkers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17738868.3A
Other languages
German (de)
French (fr)
Other versions
EP3403093A1 (en
Inventor
Joshua Labaer
Ji Qiu
Jie Wang
Garrick Wallstrom
Jin Park
William Rom
Harvey Pass
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York University NYU
Arizona State University ASU
Arizona State University Downtown Phoenix campus
Original Assignee
New York University NYU
Arizona State University ASU
Arizona State University Downtown Phoenix campus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York University NYU, Arizona State University ASU, Arizona State University Downtown Phoenix campus filed Critical New York University NYU
Publication of EP3403093A1 publication Critical patent/EP3403093A1/en
Publication of EP3403093A4 publication Critical patent/EP3403093A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP17738868.3A 2016-01-12 2017-01-11 PLASMATIC AUTO-ANTIBODY BIOMARKERS FOR THE DIAGNOSIS OF LUNG CANCER Withdrawn EP3403093A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662277786P 2016-01-12 2016-01-12
PCT/US2017/013037 WO2017123648A1 (en) 2016-01-12 2017-01-11 Plasma autoantibody biomarkers for diagnosis of lung cancer

Publications (2)

Publication Number Publication Date
EP3403093A1 EP3403093A1 (en) 2018-11-21
EP3403093A4 true EP3403093A4 (en) 2019-08-07

Family

ID=59311658

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17738868.3A Withdrawn EP3403093A4 (en) 2016-01-12 2017-01-11 PLASMATIC AUTO-ANTIBODY BIOMARKERS FOR THE DIAGNOSIS OF LUNG CANCER

Country Status (4)

Country Link
US (2) US20190004051A1 (en)
EP (1) EP3403093A4 (en)
CN (1) CN108885208A (en)
WO (1) WO2017123648A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3054299B1 (en) 2010-08-13 2021-03-24 Arizona Board of Regents, a body corporate acting on behalf of Arizona State University Biomarkers for the early detection of breast cancer
US10435747B2 (en) 2014-08-19 2019-10-08 Arizona Board Of Regents On Behalf Of Arizona State University Radiation biodosimetry systems
WO2016094558A1 (en) 2014-12-09 2016-06-16 Arizona Board Of Regents On Behalf Of Arizona State University Plasma autoantibody biomarkers for basal like breast cancer
WO2017048709A1 (en) 2015-09-14 2017-03-23 Arizona Board Of Regents On Behalf Of Arizona State University Generating recominant affinity reagents with arrayed targets
WO2017218677A2 (en) 2016-06-14 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Identification and medical applications of anti-citrullinated-protein antibodies in rheumatoid arthritis
US10648978B2 (en) 2017-02-09 2020-05-12 Mayo Foundation For Medical Education And Research Methods for detecting novel autoantibodies in Crohn's disease
WO2018156553A1 (en) 2017-02-21 2018-08-30 Arizona Board Of Regents On Behalf Of Arizona State University A method for targeted protein quantification by bar-coding affinity reagents with unique dna sequences
EP3606507A4 (en) * 2017-04-03 2020-11-11 CDI Laboratories Inc. SEROLOGICAL BIOMARKERS FOR EARLY DIAGNOSIS OF LUNG CANCER
CN108333375B (en) * 2018-04-20 2020-08-11 山东省千佛山医院 Reagent kit for diagnosing lung non-small cell cancer early stage specific autoantibody panel
CN108548923B (en) * 2018-04-20 2020-10-23 山东省千佛山医院 Early-stage specific autoantibody panel diagnostic kit for small cell lung cancer
CN110108877B (en) * 2019-05-30 2020-06-16 四川大学华西医院 The use of FAM172A autoantibody detection reagent in the preparation of lung cancer screening kit
CN110579611B (en) * 2019-09-18 2023-01-31 郑州大学 A combined detection serum marker, kit and detection method for early screening and diagnosis of lung cancer
CN110656168B (en) * 2019-09-30 2023-04-18 中南大学 COPD early diagnosis marker and application thereof
CN113138273B (en) * 2020-01-17 2024-06-18 孟民杰 A kit for rapid screening of lung cancer and immune targeted therapy detection and its use
CN113311162B (en) * 2021-04-29 2024-07-16 安徽省肿瘤医院 Combination and application of plasma exosome autoantibodies for distinguishing benign and malignant pulmonary nodules
CN113604576B (en) * 2021-10-09 2022-01-07 上海晟燃生物科技有限公司 Lung adenocarcinoma detection kit, storage medium and electronic device
WO2024044791A2 (en) * 2022-08-26 2024-02-29 Arizona Board Of Regents On Behalf Of Arizona State University Anti-microbial antibody signatures related to lung tumors and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009085237A2 (en) * 2007-12-21 2009-07-09 Cell Genesys, Inc. Methods and compositions for identifying lung cancer or a humoral immune response against lung cancer
US20150354008A1 (en) * 2005-04-14 2015-12-10 Trustees Of Boston University Diagnostic for lung disorders using class prediction

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110224313A1 (en) * 2008-06-05 2011-09-15 British Columbia Cancer Agency Branch Compositions and methods for classifying lung cancer and prognosing lung cancer survival
US20120100558A1 (en) * 2008-09-08 2012-04-26 Hanash Samir M Lung cancer diagnosis
WO2011109440A1 (en) * 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings Biomarkers for theranostics
CA2789494C (en) * 2010-02-10 2021-08-17 The Regents Of The University Of California Salivary biomarkers for lung cancer detection
CA2751835A1 (en) * 2010-09-05 2012-03-05 University Health Network Methods and compositions for the classification of non-small cell lung carcinoma
EP2678447A1 (en) * 2011-02-23 2014-01-01 Miami Mice Research Corp Cancer diagnosis and treatment
WO2014127006A1 (en) * 2013-02-12 2014-08-21 Texas Tech University System Composition and method for diagnosis and immunotherapy of lung cancer
EP2806274A1 (en) * 2013-05-24 2014-11-26 AIT Austrian Institute of Technology GmbH Lung cancer diagnostic method and means

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150354008A1 (en) * 2005-04-14 2015-12-10 Trustees Of Boston University Diagnostic for lung disorders using class prediction
WO2009085237A2 (en) * 2007-12-21 2009-07-09 Cell Genesys, Inc. Methods and compositions for identifying lung cancer or a humoral immune response against lung cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHAPMAN C J ET AL: "Autoantibodies in lung cancer: possibilities for early detection and subsequent cure", THORAX, BMJ PUBLISHING GROUP, GB, vol. 63, no. 3, 1 March 2008 (2008-03-01), pages 228 - 233, XP008130047, ISSN: 0040-6376, [retrieved on 20071011], DOI: 10.1136/THX.2007.083592 *
P. BOYLE ET AL: "Clinical validation of an autoantibody test for lung cancer", ANNALS OF ONCOLOGY, vol. 22, no. 2, 30 July 2010 (2010-07-30), pages 383 - 389, XP055213539, ISSN: 0923-7534, DOI: 10.1093/annonc/mdq361 *
See also references of WO2017123648A1 *
TURECI O ET AL: "Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1", CANCER LETTERS, NEW YORK, NY, US, vol. 236, no. 1, 8 May 2006 (2006-05-08), pages 64 - 71, XP027883654, ISSN: 0304-3835, [retrieved on 20060508] *

Also Published As

Publication number Publication date
EP3403093A1 (en) 2018-11-21
US20250216393A1 (en) 2025-07-03
WO2017123648A1 (en) 2017-07-20
US20190004051A1 (en) 2019-01-03
CN108885208A (en) 2018-11-23

Similar Documents

Publication Publication Date Title
EP3403093A4 (en) PLASMATIC AUTO-ANTIBODY BIOMARKERS FOR THE DIAGNOSIS OF LUNG CANCER
IL270717A (en) Biomarkers for the diagnosis of lung cancer
IL285218A (en) Biomarkers for the diagnosis of ovarian cancer
HUE047951T2 (en) Blood-based biomarkers for the diagnosis of atherosclerotic coronary artery disease
EP3692164A4 (en) METHYLATION MARKERS FOR CANCER DIAGNOSIS
MA42238A (en) BLADDER CANCER DIAGNOSIS METHODS
EP4022094A4 (en) BIOMARKERS FOR THE DIAGNOSIS OF LUNG CANCER
EP3427066A4 (en) LIPID BIOMARKERS FOR CANCER DIAGNOSIS
EP3474736A4 (en) OLFACTORY DETECTOR FOR EARLY DIAGNOSIS OF OVARY CANCER.
EP3427051A4 (en) PROTEIN AND SELF-ANTIBODY BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF LUNG CANCER
EP2948769A4 (en) PLATELET BIOMARKERS USED IN THE DIAGNOSIS OF CANCER
EP3690063C0 (en) DIAGNOSIS OF LUNG CANCER
EP3335041A4 (en) BIOMARKERS FOR THE TREATMENT OF PELADE
EP3679069C0 (en) ANTIBODIES FOR CANCER DIAGNOSIS
EP3479770A4 (en) ULTRASOUND ENDOSCOPE
GB201814350D0 (en) Diagnosis of cancer
IL264542A (en) Diagnostic methods for gynecological tumors
EP3479773A4 (en) ULTRASOUND ENDOSCOPE
EP3426241A4 (en) DIAGNOSTIC METHODS FOR CANCER
DK3580567T3 (en) IN VITRO PROCEDURE FOR DIAGNOSIS OF LUNG CANCER
EP3573650A4 (en) DIAGNOSIS OF SCLERODERMIA
EP3565560A4 (en) PREDICTIVE AND DIAGNOSTIC PROCEDURES FOR PROSTATE CANCER
FR3047059B1 (en) CONNECTION ASSEMBLY FOR TUBE
SI3156798T1 (en) A novel assay for the diagnosis of helminth infections
EP3839513C0 (en) USE OF TRANSCRIPTION FACTOR-DNA COMPLEXES FOR THE DETECTION OF CANCER

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180806

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20190709

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/53 20060101AFI20190703BHEP

Ipc: C07K 16/32 20060101ALI20190703BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200807

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20201218